 |
|
|
| |
Final Results From Phase 3 Portion in Phase 2/3 Study of Elbasvir/Grazoprevir in Hepatitis C Genotype 1-Infected Japanese Patients
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Fumitaka Suzuki1; Yoshiyasu Karino2; Kazuaki Chayama3; Norifumi Kawada4; Takeshi Okanoue5; Yoshito Itoh6; Satoshi Mochida7; Hidenori Toyoda8; Hitoshi Yoshiji9; Shintaro Takaki10; Naoyoshi Yatsuzuka11; Etsuo Yodoya11; Go Fujimoto11; Janice Wahl12; Michael Robertson12; Stuart Black12; Hiromitsu Kumada1
1Department of Hepatology, Toranomon Hospital, Tokyo, Japan; 2Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan; 3Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan; 4Department of Hepatology, Osaka City University Medical School, Osaka, Japan; 5Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan; 6Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan; 7Department of Gastroenterology and Hepatology, Saitama Medical University, Saitama, Japan; 8Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan; 9Third Department of Internal Medicine, Nara Medical University, Nara, Japan; 10Department of Gastroenterology/Liver Center, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan; 11MSD K.K., Tokyo, Japan; 12Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
